Bristol Myers Squibb Co., based in Princeton, NJ, employs 34,100 staff and develops biopharmaceuticals across various therapeutic classes, including oncology and immunology. Key products include Eliquis and Opdivo, with a strong pipeline featuring Krazati and KarXT.
BMY has been in the news recently: Bristol Myers Squibb is supported by Halozyme Therapeutics in the development of a subcutaneous formulation for its Opdivo drug, with a marketing decision expected in Europe by June 2, 2025. Additionally, Leerink Partners has cautioned that Bristol Myers Squibb may experience significant tariff impacts that could increase drug costs for consumers.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
